Vaccine plus Keytruda for lung cancer after surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer that is stage II, IIIA, or IIIB (N2) and has not been treated yet.
- You should have already received chemotherapy plus pembrolizumab before surgery, and after surgery, the cancer was not completely gone.
- Your tumor must not have certain gene changes (like EGFR or ALK) that would make other targeted treatments more appropriate.
- You must not have had prior immunotherapy (like Keytruda) or a cancer vaccine for any condition.
- You need to be in generally good health (able to perform daily activities with little or no help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) along with 2 or 4 cycles of chemotherapy before surgery can help shrink tumors and improve outcomes for people with early-stage (stage II-IIIB) non-small cell lung cancer. The goal is to make surgery more effective and possibly reduce the chance of cancer coming back.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial tests a new combination of drugs (Keytruda with or without chemotherapy) to see if it works better for advanced lung cancer. It's for people who haven't had immunotherapy or chemotherapy for their cancer that has spread.
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab and chemotherapy for people with advanced squamous non-small cell lung cancer that has spread. The goal is to see if adding the vaccine helps the immune system fight the cancer better.
This trial tests whether giving a personalized cancer vaccine (Intismeran) with or without an immunotherapy drug (pembrolizumab) after lung cancer surgery can help prevent the cancer from coming back in patients with early-stage, high-risk non-small cell lung cancer.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.